Screener
Avalo Therapeutics AVTX Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's free cash flow margin?
- Avalo Therapeutics (AVTX) reported free cash flow margin of -11,123.8% in Q4 2024.
- How has Avalo Therapeutics's free cash flow margin changed year-over-year?
- Avalo Therapeutics's free cash flow margin decreased by 594.4% year-over-year, from -1,602% to -11,123.8%.
- What is the long-term trend for Avalo Therapeutics's free cash flow margin?
- Over 3 years (2020 to 2024), Avalo Therapeutics's free cash flow margin has grown at a 163.8% compound annual growth rate (CAGR), from -606% to -11,123.8%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Avalo Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude